新辅助化疗前后和复发后晚期卵巢高级别浆液性癌组织中IKKε、Ki67、ALDH1的表达及意义  

Expression and Significance of IKKε,Ki67 and ALDH1 in Advanced Ovarian High Grade Plasmacytoma Tissue Before and After Neoadjuvant Chemotherapy and Recurrence

作　　者：高羽 李季[2,3] 庞露 张鹏新[4] 高景春 Gao Yu;Li Ji;Pang Lu;Zhang Peng-xin;Gao Jing-chun(Department of Medical Oncology,Dalian Central Hospital Affiliated to Dalian Medical University,Dalian 116033,Liaoning Province,China;Department of Obstetrics and Gynecology,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,Liaoning Province,China;Dalian Women and Children Medical Center,Dalian 116037,Liaoning Province,China;Department of Pathology,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,Liaoning Province,China)

机构地区：[1]大连医科大学附属大连市中心医院肿瘤内科,辽宁大连116033 [2]大连医科大学附属第一医院妇产科,辽宁大连116011 [3]大连市妇女儿童医疗中心,辽宁大连116037 [4]大连医科大学附属第一医院病理科,辽宁大连116011

出　　处：《中外医药研究》2023年第1期132-134,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

基　　金：大连市医学科学研究计划(编号:1911010)。

摘　　要：目的:分析新辅助化疗前后和复发后晚期卵巢高级别浆液性癌组织中核因子κB激酶抑制剂ε(IKKε)、肿瘤增殖抗原(Ki67)、乙醛脱氢酶(ALDH1)蛋白表达及意义。方法:选取2005年1月—2017年1月大连医科大学附属第一医院及附属大连市中心医院妇科收治的经术后病理证实为卵巢高级别浆液性癌患者30例为观察对象,根据临床治疗方式将患者分为新辅助化疗组(n=20)和复发组(n=10)。比较新辅助化疗组、复发组IKKε、Ki67、ALDH1表达情况。结果:新辅助化疗组患者化疗后IKKε、Ki67阳性表达率低于化疗前,差异有统计学意义(P<0.05);复发组患者化疗前和复发后IKKε、Ki67、ALDH1阳性表达率比较,差异无统计学意义(P>0.05)。结论:IKKε可能参与调控新辅助化疗和复发期间卵巢癌细胞的活性,Ki67可用来预示新辅化疗及复发后肿瘤的“消长”,ALDH1的临床意义仍有待研究和探讨。Objective:To analyze the expression and significance of nuclear factorκB kinase inhibitorε(IKKε),tumor proliferation antigen(Ki67),and acetaldehyde dehydrogenase(ALDH1)proteins in advanced ovarian high grade plasmacytoma tissues before and after neoadjuvant chemotherapy and after recurrence.Methods:Thirty patients with postoperative pathologically confirmed high grade plasmacytoma of the ovary admitted to the Department of Gynecology of the First Affiliated Hospital of Dalian Medical University and Affiliated Dalian Central Hospital from January 2005 to January 2017 were selected as observation subjects,and the patients were divided into neoadjuvant chemotherapy group(n=20)and recurrence group(n=10)according to clinical treatment modality.The expression of IKKε,Ki67 and ALDH1 in the neoadjuvant chemotherapy group and the recurrence group were compared.Results:The positive expression rates of IKKεand Ki67 in patients in the neoadjuvant chemotherapy group were lower than those before chemotherapy,and the differences were statistically significant(P<0.05).The differences were not statistically significant(P>0.05)when comparing the positive expression rates of IKKε,Ki67 and ALDH1 in patients in the relapse group before and after chemotherapy.Conclusion:IKKεmay be involved in regulating the activity of ovarian cancer cells during neoadjuvant chemotherapy and recurrence,Ki67 may be used to predict the"growth and decline"of tumor after neoadjuvant chemotherapy and recurrence,and the clinical significance of ALDH1 remains to be studied and explored.

关 键 词：核因子κB激酶抑制剂ε 肿瘤增殖抗原 乙醛脱氢酶 化疗耐药 卵巢上皮性癌 

分 类 号：R73[医药卫生—肿瘤]